Regulus Therapeutics Inc. (NASDAQ:RGLS) Insider Sells $39,620.70 in Stock

Regulus Therapeutics Inc. (NASDAQ:RGLS) insider Preston Klassen sold 31,445 shares of the stock in a transaction that occurred on Monday, January 13th. The stock was sold at an average price of $1.26, for a total value of $39,620.70. Following the completion of the transaction, the insider now owns 36,055 shares of the company’s stock, valued at $45,429.30. The trade was a 46.59 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Regulus Therapeutics Trading Up 3.7 %

RGLS traded up $0.05 during mid-day trading on Wednesday, hitting $1.27. 283,082 shares of the stock were exchanged, compared to its average volume of 348,120. The firm’s fifty day moving average is $1.53 and its two-hundred day moving average is $1.59. Regulus Therapeutics Inc. has a 1-year low of $1.08 and a 1-year high of $3.79. The company has a market cap of $83.19 million, a PE ratio of -1.19 and a beta of 1.60.

Regulus Therapeutics (NASDAQ:RGLS) last issued its quarterly earnings results on Thursday, November 7th. The biopharmaceutical company reported ($0.21) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.18) by ($0.03). As a group, research analysts anticipate that Regulus Therapeutics Inc. will post -0.88 earnings per share for the current year.

Hedge Funds Weigh In On Regulus Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in RGLS. NEA Management Company LLC acquired a new stake in shares of Regulus Therapeutics in the third quarter valued at $10,154,000. Point72 Asset Management L.P. purchased a new position in shares of Regulus Therapeutics in the 3rd quarter valued at about $1,403,000. Bank of New York Mellon Corp acquired a new position in shares of Regulus Therapeutics during the second quarter worth about $352,000. The Manufacturers Life Insurance Company purchased a new stake in shares of Regulus Therapeutics during the third quarter worth approximately $204,000. Finally, Tyche Wealth Partners LLC increased its stake in shares of Regulus Therapeutics by 920.6% during the third quarter. Tyche Wealth Partners LLC now owns 106,089 shares of the biopharmaceutical company’s stock worth $167,000 after buying an additional 95,694 shares during the period. Hedge funds and other institutional investors own 92.38% of the company’s stock.

Analysts Set New Price Targets

RGLS has been the topic of several recent analyst reports. StockNews.com raised Regulus Therapeutics to a “sell” rating in a research note on Tuesday, September 17th. HC Wainwright reaffirmed a “buy” rating and issued a $10.00 target price on shares of Regulus Therapeutics in a research report on Monday, November 11th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $10.80.

About Regulus Therapeutics

Regulus Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease.